Google DeepMind Launches AlphaGenome 2, a DNA Model That Reads Variants Cell by Cell
By Ganesh Karki
Key facts
- Section
- Tech & AI
- Country
- UK
- Published
- 17 Nov 2026
Google DeepMind has launched AlphaGenome 2, a DNA model that predicts how a genetic variant affects different cells and tissues. The announcement came on 11 November 2026.
The model was trained on more than 107 million single-cell profiles across 68 tissues. It can read DNA sequences of up to one million base pairs and predict gene expression, accessibility, splicing, contact maps and methylation, cell by cell.
AlphaGenome 2 at a glance
| Detail | Information |
|---|---|
| Announced | 11 November 2026 |
| Training data | 107 million+ cell profiles, 68 tissues |
| Sequence length | Up to 1 million base pairs |
| Predicts | Gene expression, accessibility, splicing, contact maps, methylation |
| Benchmark | TenK10K: causal variants found 30% of the time, vs 16% for AlphaGenome 1 |
| Access | API for non-commercial research; commercial use in private preview |
| Clinical use | Not approved |
What happened
Most DNA models treat a genetic variant as having one effect. AlphaGenome 2 treats it as having different effects in different cells, which is closer to how biology actually works. A variant that raises disease risk in one tissue may do nothing in another, and the model is built to tell the difference.
On the TenK10K benchmark, the model identified causal variants 30 percent of the time, against 16 percent for the first AlphaGenome. Independent testing by CellCog found it works well on small datasets and is strong at predicting gene expression.
Why it matters
Finding the variant that actually causes a disease, among thousands of candidates, is one of the slowest steps in genetics. A model that can rank candidates cell by cell could speed up that search, and with it the search for new drug targets.
DeepMind is making the model available through an API for non-commercial research, with commercial access in private preview. That puts a powerful research tool in the hands of academic labs first, rather than locking it behind a commercial licence.
What is not confirmed
There is no date for general commercial release, and the model is not approved for clinical use. The benchmark results come from DeepMind's own testing and one independent check by CellCog, not from a broad independent validation.
Sources
Google DeepMind, official announcement, 11 November 2026; Unite.ai.
Sources and references
Information checked: 17 November 2026
Related stories
SpaceX Falcon 9 NROL-136 Launch: What to Watch on 21 November
SpaceX Falcon 9 NROL-136 launch is scheduled for 21 November from Vandenberg, carrying reconnaissance satellites for the National Reconnaissance Office.
20 November 2026AO3 Returns After 17 Days Offline After Security Breach
AO3 returns after 17 days offline following a security incident, with some features still disabled, and went down again briefly on 19 November for maintenance.
20 November 2026ChatGPT for Accounting Launches With QuickBooks Link
ChatGPT for Accounting launched this week, connecting the chatbot to QuickBooks, Xero and NetSuite so finance teams can reconcile books and close the month.
20 November 2026Tesla Cybercab Rides Begin in Dallas With V1.5 Cars
Tesla Cybercab rides began in Dallas on 19 November, the second city after Austin to get the steering wheel-free robotaxi, with upgraded V1.5 vehicles.